News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EPIX buy 3.1628
normal chart
log chart
$EPIX - Nice move monday and intrday pullback, now ready to continue higher
|
Followers
|
16
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1332
|
|
Created
|
08/31/07
|
Type
|
Free
|
| Moderators | |||
EPIX Pharmaceuticals, Inc.,
a biopharmaceutical company, engages in the discovery and development of therapeutics through the use of its proprietary silico drug discovery platform. The company's therapeutic product candidates in development include PRX-08066 that completed Phase IIa clinical trial for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease; PRX-03140, which is in Phase IIa clinical trial for the treatment of Alzheimer's disease; PRX-00023, which is in Phase IIb clinical trial for the treatment of depressive disorder; and PRX-07034, which is in Phase Ib clinical trial for the treatment of obesity and cognitive impairment associated with schizophrenia. Its imaging agents comprise Vasovist, an injectable intravascular contrast agent that provides enhanced imaging of the vascular system using magnetic resonance angiography; and EP-2104R that enables the identification of blood clots using MRI. EPIX Pharmaceuticals has collaborations with SmithKline Beecham Corporation; Amgen, Inc.; Cystic Fibrosis Foundation Therapeutics Incorporated; and Bayer Schering Pharma AG, Germany. The company was founded in 1988 as Metacorp, Inc. and changed its name to METASYN, Inc. in May 1989. It further changed its name to EPIX Medical, Inc. in May 1996 and then to EPIX Pharmaceuticals Inc. in September 2004. EPIX Pharmaceuticals Inc. is headquartered in Lexington, Massachusetts.
Homepage EPIX Pharmaceuticals: http://www.epixpharma.com/ - (781) 761-7600
Yahoo Key Statistics: http://finance.yahoo.com/q/ks?s=EPIX.OB - Enterprise Value August 19, 2009: $86.49M
)
Factsheet Epix December 2007
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=epix
Company Information
Recent News
The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer's Disease. The patient was enrolled initially in a two week Phase 2a study in August 2007 where she received 100 mg per day of PRX-03140 in combination with her normal daily dose of Aricept((R))(10 mg). Based on the marked progress during the original two week study, the patient's daughter sought continued compassionate use of PRX-03140 for her mother and a protocol was submitted to the FDA and approved. The progress seen in the first 2-week study has continued during the past two years (19 months of dosing) and four FDA approved 6-month open label extensions. The latest open label extension will be administered under a new Physician-Sponsored IND under the supervision of Dr. Lucy Hornstein(1). "When I was approached by the patient's daughter to continue the compassionate use therapy of PRX-03140 for her mother, I was compelled by the progress her mother had experienced and the overall apparent safety of the drug," notes Dr. Hornstein.
On July 20, 2009, EPIX Pharmaceuticals, Inc. (the "Company") entered into an Assignment for the Benefit of Creditors (the "Assignment") in accordance with Massachusetts law. The purpose of the Assignment is to conclude the Company's operations and provide for an orderly liquidation of its assets. The Assignment is a common law business liquidation mechanism under Massachusetts law that is an alternative to a formal bankruptcy proceeding. Under the terms of the Assignment, the Company transferred all of its assets to an assignee for orderly liquidation and distribution of the proceeds to the Company's creditors. The designated assignee for the Company is Joseph F. Finn, Jr. at Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481.
The PRX-03140 program will be sold at auction on Wednesday, October 21 at 3 pm EDT. Please contact Joseph F. Finn, Jr. at 781-237-8840 if you are interested in participating in the auction.
SOURCE Joseph F. Finn, Jr., C.P.A.
EPIX PHARMACEUTICALS ANNOUNCES THE P2Y2 GASTROINTESTINAL PROGRAM
Sep 01, 2009 (AsiaPulse via COMTEX) -- MEDIA RELEASE PR35934
(Full text of statement. Contact details below.)
EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
WELLESLEY HILLS, Mass., Sept. 2 /PRNewswire-AsiaNet/ --
Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the P2Y2 Gastrointestinal Early Development Candidate Program will be part of the intellectual property offered for sale at the September 30, 2009 auction.
The P2Y2, an Early Development Candidate Program, is a small molecule, oral, non-absorbed agonist for treatment of constipation.
The intellectual property, regulatory dossier and clinical inventory will be sold at auction on September 30, 2009.
Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.
He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net
SOURCE:: Joseph F. Finn, Jr., C.P.A.
Share Structure and Company Information
| EPIX Pharmaceuticals, Inc. 4 Maguire Road Lexington, MA 02421
|
|
